Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models-Reference-Cited by-同舟云学术

Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models

Published:2020-06-05 Issue:13 Volume:63 Page:7293-7325
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lücking Ulrich¹^ORCID,Wortmann Lars¹^ORCID,Wengner Antje M.¹,Lefranc Julien¹^ORCID,Lienau Philip¹,Briem Hans¹,Siemeister Gerhard¹,Bömer Ulf¹,Denner Karsten¹,Schäfer Martina¹,Koppitz Marcus¹,Eis Knut¹^ORCID,Bartels Florian¹^ORCID,Bader Benjamin¹,Bone Wilhelm¹,Moosmayer Dieter¹,Holton Simon J.¹,Eberspächer Uwe¹,Grudzinska-Goebel Joanna¹,Schatz Christoph¹,Deeg Gesa¹,Mumberg Dominik¹,von Nussbaum Franz¹

Affiliation:

1. Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00369

Reference51 articles.

1. The DNA-damage response in human biology and disease

2. The DNA Damage Response: Making It Safe to Play with Knives

3. Molecular Mechanisms of Mammalian DNA Repair and the DNA Damage Checkpoints